Biomarkers /
CTNNA3
Overview
CTNNA3 is altered in 0.17% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast neoplasm, breast invasive lobular carcinoma, and ganglioglioma having the greatest prevalence of alterations [3].
The most common alterations in CTNNA3 are CTNNA3 Mutation (1.45%), CTNNA3 Amplification (0.70%), CTNNA3 Loss (0.54%), CTNNA3 I411V (0.08%), and CTNNA3 M435V (0.08%) [3].
Clinical Trials
Significance of CTNNA3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.